Monga Sheelu, Denora Nunzio, Laquintana Valentino, Yashaev Rami, Weizman Abraham, Gavish Moshe
Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 31096, Israel.
Department of Pharmacy-Pharmaceutical Sciences, University of Bari "A. Moro", Orabona, St. 4, 70125 Bari, Italy.
Biology (Basel). 2021 Nov 15;10(11):1183. doi: 10.3390/biology10111183.
Parkinson's disease (PD) is a progressive neurodegenerative disorder which is characterized by the degeneration of dopaminergic neurons in substantia nigra (SN). Oxidative stress or reactive oxygen species (ROS) generation was suggested to play a role in this specific type of neurodegeneration. Therapeutic options which can target and counteract ROS generation may be of benefit. TSPO ligands are known to counteract with neuro-inflammation, ROS generation, apoptosis, and necrosis. In the current study, we investigated an in vitro cellular PD model by the assessment of 6-hydroxydopamine (6-OHDA, 80 µM)-induced PC12 neurotoxicity. Simultaneously to the exposure of the cells to 6-OHDA, we added the TSPO ligands CB86 and CB204 (25 µM each) and assessed the impact on several markers of cell death. The two ligands normalized significantly (57% and 52% respectively, from 44%; whereas the control was 68%) cell proliferation at different time points from 0-24 h. Additionally, we evaluated the effect of these two TSPO ligands on necrosis using propidium iodide (PI) staining and found that the ligands inhibited significantly the 6-OHDA-induced necrosis. As compared to control, the red count was increased up to 57-fold whereas CB86 and CB204 inhibited to 2.7-fold and 3.2-fold respectively. Necrosis was also analyzed by LDH assay which showed significant effect. Both assays demonstrated similar potent anti-necrotic effect of the two TSPO ligands. Reactive oxygen species (ROS) generation induced by 6-OHDA was also inhibited by the two TSPO ligand up to 1.3 and 1.5-fold respectively, as compared to 6-OHDA group. CB86 and CB204 inhibited also normalized the cell viability up to 1.8-fold after the exposure to 6-OHDA, as assessed by XTT assay. The two TSPO ligands also inhibited apoptosis significantly (1.3-fold for both) as assessed by apopxin green staining. In summary, it appears that the two TSPO ligands CB86 and CB204 can suppress cell death of PC12 induced by 6-OHDA. The results may be relevant to the use of these two TSPO ligands as therapeutic option neurodegenerative diseases like PD.
帕金森病(PD)是一种进行性神经退行性疾病,其特征是黑质(SN)中多巴胺能神经元的退化。氧化应激或活性氧(ROS)的产生被认为在这种特定类型的神经退行性变中起作用。能够靶向并对抗ROS产生的治疗选择可能有益。已知TSPO配体可对抗神经炎症、ROS产生、细胞凋亡和坏死。在本研究中,我们通过评估6-羟基多巴胺(6-OHDA,80µM)诱导的PC12神经毒性建立了一种体外细胞PD模型。在细胞暴露于6-OHDA的同时,我们添加了TSPO配体CB86和CB204(各25µM),并评估其对几种细胞死亡标志物的影响。这两种配体在0-24小时的不同时间点显著使细胞增殖恢复正常(分别为57%和52%,起始为44%;而对照组为68%)。此外,我们使用碘化丙啶(PI)染色评估了这两种TSPO配体对坏死的影响,发现这些配体显著抑制了6-OHDA诱导的坏死。与对照组相比,红色计数增加至57倍,而CB86和CB204分别抑制至2.7倍和3.2倍。还通过乳酸脱氢酶(LDH)测定分析坏死情况,结果显示有显著效果。两种测定均显示这两种TSPO配体具有相似的强效抗坏死作用。与6-OHDA组相比,这两种TSPO配体分别将6-OHDA诱导的活性氧(ROS)产生抑制了1.3倍和1.5倍。通过XTT测定评估,CB86和CB204在细胞暴露于6-OHDA后还将细胞活力恢复正常达1.8倍。通过Apopxin绿色染色评估,这两种TSPO配体也显著抑制了细胞凋亡(两者均为1.3倍)。总之,似乎两种TSPO配体CB86和CB204可以抑制6-OHDA诱导的PC12细胞死亡。这些结果可能与将这两种TSPO配体用作治疗帕金森病等神经退行性疾病的选择有关。